daraxonrasib
daraxonrasib: sourced relationships with 1 company · 19 clinical trials tracked.
daraxonrasib evidence translation
What we can confirm
19 tracked trials
What it means
What to watch
Prepared research question
How could daraxonrasib → RVMD affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 3 study sponsors
Related indications
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| REVOLUTION MEDICINES, INC. (RVMD) Non-small Cell Lung Cancer (NSCLC); PDAC; Pancreatic Cancer | Phase 3 |
Clinical Trial Registry Records (19)showing 10 most recent
Expanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib
A Phase 1/2 Study of Daraxonrasib (RMC-6236) in Patients With Relapsed or Refractory RAS-Driven Tumors
Primary endpoint: Maximum tolerated dose (MTD) (Phase 1 part A)
A Multi-Institutional Phase 2 Evaluation of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
Primary endpoint: Objective Response (ORR)
A Phase 1, Open-Label, Dose-Escalation and Expansion Study of SNV1521 in Combination With RAS Inhibition in Participants With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Primary endpoint: Safety and tolerability of SNV1521 plus daraxonrasib: treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities
A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Primary endpoint: Progression free survival (PFS)
A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion
Primary endpoint: Part 1: Number of participants who achieve Objective Response (OR)
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma
Primary endpoint: Progression free survival (PFS)
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors
Primary endpoint: Number of patients with adverse events (AEs)
Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Primary endpoint: Number of patients with adverse events (AEs)
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Primary endpoint: Disease-Free Survival (DFS) per Investigator
Frequently asked questions
Which companies have sourced relationships with daraxonrasib?
daraxonrasib has dated SEC/FDA relationship records for REVOLUTION MEDICINES, INC..
How many clinical trials involve daraxonrasib?
BioSniper tracks 19 clinical trials involving daraxonrasib.